Investment Considerations Tonix Pharmaceuticals is poised to capitalize on the growing demand for fibromyalgia treatments with its lead candidate, TNX-102 SL, which has demonstrated strong Phase 3 clinical results and received FDA Fast Track designation. The company’s diversified pipeline, targeting CNS disorders, autoimmune diseases, and cocaine intoxication, offers multiple avenues for growth and reduces reliance … Continue reading “Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP)”
Symbol | Release | Time | Source |
---|---|---|---|
{{ release.qmtopics.qmsymbol[0].symbol }} | {{ release.headline }} | {{ release.datetime | amDateFormat:'hh:mm A'}} | {{ release.source }} |
SmallCapRelations is part of the IBN (InvestorBrandNetwork).